Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR

Mutual of America Capital Management LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 18.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,468 shares of the biotechnology company’s stock after purchasing an additional 4,036 shares during the quarter. Mutual of America Capital Management LLC owned 0.06% of United Therapeutics worth $11,096,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. AQR Capital Management LLC lifted its stake in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares in the last quarter. Invesco Ltd. lifted its position in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Assetmark Inc. boosted its stake in United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the period. Norges Bank bought a new position in United Therapeutics during the 2nd quarter worth about $136,453,000. Finally, Amundi raised its stake in shares of United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock valued at $107,113,000 after purchasing an additional 12,633 shares during the period. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on UTHR. UBS Group upped their price target on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $473.36 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market capitalization of $20.38 billion, a P/E ratio of 17.94, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84. The company has a 50-day simple moving average of $487.69 and a 200 day simple moving average of $416.98.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the previous year, the firm earned $6.39 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 536,864 shares of company stock valued at $255,191,362 over the last 90 days. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.